Planta Med 2019; 85(18): 1577
DOI: 10.1055/s-0039-3400421
Main Congress Poster
Poster Session 2
© Georg Thieme Verlag KG Stuttgart · New York

Genistein therapy in an animal model of estrogen deficiency

A Miklos
1   Faculty of Pharmacy, University of Medicine, Pharmacy, Sciences and Technology of Tîrgu Mureş,, Gheorghe Marinescu street 39, 540139, Tîrgu Mureş, Romania
,
A Tero-Vescan
1   Faculty of Pharmacy, University of Medicine, Pharmacy, Sciences and Technology of Tîrgu Mureş,, Gheorghe Marinescu street 39, 540139, Tîrgu Mureş, Romania
,
C Filip
1   Faculty of Pharmacy, University of Medicine, Pharmacy, Sciences and Technology of Tîrgu Mureş,, Gheorghe Marinescu street 39, 540139, Tîrgu Mureş, Romania
,
BE Ősz
1   Faculty of Pharmacy, University of Medicine, Pharmacy, Sciences and Technology of Tîrgu Mureş,, Gheorghe Marinescu street 39, 540139, Tîrgu Mureş, Romania
› Author Affiliations
Further Information

Publication History

Publication Date:
20 December 2019 (online)

 

Genistein is a partial β2-estrogen receptor agonist, having a similar endogenous affinity to 17β-estradiol [1]. Due to the hormonal decline in postmenopausal women, the incidence of bone mass loss increases, together with mammary gland atrophy, mouth and vaginal mucosa dryness [2].

To establish the effects of genistein in ovariectomized female rats. Forty female rats were divided into 4 groups (10 rats / group): group I: treated with 10 mg / kg/day genistein (intraperitoneally), for 8 weeks; group II: treated with 17β-estradiol for 8 weeks with 10 µg / kg/day; the group III: untreated rats and group IV: non-ovariectomized and untreated rats. Bone samples were taken from the femoral and lumbar head, mammary gland, vaginal and buccal mucosa and were histologically analyzed. The bone density evaluation was made by radiological method. All the experiments and research protocols were approved by the Research Ethics Comitee.

Results: In group III the imaging results show a slight bone demineralization at the level of the femoral head compared to the other groups. Bone histological analysis confirms bone loss in group III and in group I the bone density is lower than in groups II and IV. Regarding the mammary gland and vaginal mucosa, substitution treatment with estradiol produces hypertrophy, whereas genistein prevents oral mucosal atrophy at this level, but does not reduce vaginal and mammary gland atrophy.

The effects of genistein on bone density are beneficial and the reduced effects on the mammary gland and vaginal mucosa make it useful in long-term treatment in postmenopausal women.

 

  • References

  • 1 Li XL, Sui L, Lin FH, Lian Y, Ai LZ, Zhang Y. Differential effects of genistein and 8-prenylgenistein on reproductive tissues in immature female mice. Pharm Biol 2019; 57: 226-230
    CrossrefPubMedGoogle Scholar
  • 2 Panay N, Palacios S, Bruyniks N, Particco M, Nappi RE. Symptom severity and quality of life in the management of vulvovaginal atrophy in postmenopausal women. Maturitas 2019; 124: 55-61
    CrossrefPubMedGoogle Scholar